There is currently no way to completely get rid of HSV-2. The virus embeds itself in nerve cells, where it remains for life beyond the reach of both the immune system and existing medications. But while a cure doesn’t exist yet, effective treatments can dramatically reduce outbreaks, lower the chance of spreading the virus to a partner, and for many people, make the infection a manageable, minor part of life.
Why HSV-2 Can’t Be Eliminated From the Body
After the initial infection, HSV-2 travels along nerve fibers and settles into clusters of nerve cells near the base of the spine called the sacral ganglia. Once there, the virus enters a dormant state called latency. It essentially goes to sleep inside neurons, producing almost none of the proteins that would normally alert your immune system to its presence. Your body can’t find it, and antiviral medications only work on actively replicating virus, so they can’t touch it either.
Periodically, the virus wakes up and travels back down nerve fibers to the skin’s surface. Sometimes this causes visible sores. Other times, the virus reaches the skin without producing any noticeable symptoms at all. During the first six months of infection, this “asymptomatic shedding” can happen on 20% to 40% of days. Over time it decreases, but even with a long-standing infection, shedding still occurs on roughly 5% to 20% of days. This is why transmission can happen even when no outbreak is visible.
What Daily Antiviral Therapy Does
The most effective strategy for managing HSV-2 is daily suppressive antiviral therapy. Taking a low dose of an antiviral medication every day reduces outbreak frequency, shortens outbreaks that do occur, and lowers the rate of transmission to sexual partners. The CDC notes that daily valacyclovir decreases HSV-2 transmission in couples where one partner is positive and the other is not. Suppressive therapy is the single most impactful step you can take if outbreaks are frequent or if reducing transmission risk is a priority.
There’s also an episodic approach: taking a higher dose of antiviral medication at the first sign of an outbreak (tingling, itching, or redness) and continuing for a few days. This shortens the outbreak and reduces its severity but doesn’t do anything to prevent shedding between outbreaks. Most people who experience more than a few outbreaks per year find daily suppressive therapy more practical and effective than treating each episode individually.
Resistance to standard antivirals is uncommon in people with healthy immune systems. It’s more of a concern for people who are immunocompromised, such as organ transplant recipients or those living with advanced HIV.
Supplements and Lifestyle Factors
L-lysine is the most studied supplement for herpes management. In a six-month double-blind, multicenter trial, participants taking oral L-lysine experienced 2.4 times fewer outbreaks than those taking a placebo, along with shorter healing times and less severe symptoms. It’s not a replacement for antiviral medication, but some people use it as an add-on, particularly if they prefer to avoid daily prescriptions and have infrequent outbreaks.
Stress, sleep deprivation, illness, and hormonal changes are common outbreak triggers. Managing stress through exercise, consistent sleep, and general health maintenance won’t eliminate the virus, but it can reduce how often it reactivates. Sun exposure is a well-known trigger for oral herpes and may play a role in genital outbreaks for some people as well.
Reducing Transmission to Partners
If you’re in a relationship where your partner doesn’t have HSV-2, a combination of strategies lowers transmission risk substantially. Daily suppressive antiviral therapy reduces viral shedding. Condoms provide an additional layer of protection, though they don’t cover all potentially affected skin. Avoiding sexual contact during active outbreaks, including the prodromal phase (the tingling or burning that sometimes precedes sores), is also important.
No single measure eliminates risk entirely, but layering these approaches together makes transmission considerably less likely. Open communication with partners allows both of you to make informed decisions about what precautions feel right.
Testing and Diagnosis Accuracy
If you’ve been diagnosed through a blood test rather than a swab of an active sore, it’s worth understanding the limitations. The most commonly used screening test for HSV-2 antibodies can produce false positives, particularly when the result falls in the “low-positive” range (an index value between 1.10 and 3.50). The CDC recommends that any result in this range be confirmed with a more specific test, such as a Western blot. If your diagnosis rests solely on a low-positive blood test and you’ve never had symptoms, confirmatory testing is a reasonable next step before starting treatment.
Connections to Other Health Risks
HSV-2 does interact with other aspects of your health in meaningful ways. A large meta-analysis of 55 studies found that people with HSV-2 are at least three times more likely to acquire HIV compared to those without it, even after controlling for sexual behavior. The inflammation and tiny breaks in skin caused by herpes, whether visible or not, create entry points for HIV. For people at elevated HIV risk, this is another reason daily suppressive therapy can be valuable.
For most people with healthy immune systems, HSV-2 doesn’t cause serious medical complications beyond the outbreaks themselves. Outbreaks typically become less frequent and less severe over time, often significantly so within the first couple of years.
Gene Therapy and Vaccine Research
The reason there’s no cure today is biological: no existing drug can reach dormant virus inside neurons. But two lines of research are actively working on that problem. Gene-editing tools are being developed to target and disable viral DNA directly inside nerve cells, essentially cutting the virus out of its hiding place. This approach has shown promise in animal studies, though human trials for genital herpes are still in early stages.
On the vaccine front, Moderna completed a Phase 1/2 clinical trial of a therapeutic vaccine candidate (mRNA-1608) in April 2025. A therapeutic vaccine wouldn’t prevent infection but could train the immune system to suppress reactivation more effectively in people who already carry the virus. Results from this trial will help determine whether the approach moves into larger studies. Neither gene therapy nor a vaccine is available yet, but both represent the most serious scientific effort to date toward either a functional cure or a way to keep the virus permanently dormant.